Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.

Core Viewpoint - Biogen's stock is rising despite a significant decline in multiple sclerosis revenue and ongoing challenges within its drug portfolio [1] Group 1: Financial Performance - Biogen reported fourth-quarter adjusted earnings and revenue that exceeded analysts' expectations [1] Group 2: Market Reaction - Investors are focusing on the positive earnings report while overlooking the declining sales and poor performance of most of Biogen's drug portfolio in the fourth quarter [1]